

Press Release

International Partnerships of InnoCellular and Applitech to Accelerate Next-Generation Cell Therapy Advancements in Asia



- International partnership for Singapore-based InnoCellular collaborates with China-based Applitech to advance cell therapy in Asia.
- This partnership aims to provide comprehensive one-stop solutions to the cell therapy community in Asia.

Singapore, March 6 2024 — Singapore-based InnoCellular Tech Pte Ltd (“InnoCellular”), an A*STAR spin-off company specializing in cell culture media, and China-based Applitech Biological Technology Co., Ltd (“Applitech”), a pioneer in equipment developer for bioreactors and consumables, are excited to announce their partnership aimed at supporting the advancement and realization of next-generation cell therapy.

Cell therapies represent groundbreaking approaches to treating a variety of diseases and medical conditions, offering promising avenues for personalized medicine and improved patient outcomes. However, the success of these therapies relies on a combination of cutting-edge technologies, including specialized cell culture media and advanced equipment for cell processing, cultivation, and manufacturing under the compliance of rigorous clinical quality controls.

By combining the two companies’ respective expertise, InnoCellular and Applitech are driven to provide comprehensive solutions to researchers and biopharmaceutical companies engaged in cell therapy development. InnoCellular's expertise in developing customized cell culture media solutions perfectly complements Applitech's offerings of innovative equipment, including bioreactors and cell culture bags, ensuring seamless integration and optimal performance throughout the entire cell therapy manufacturing process.

As part of their collaboration, InnoCellular will make its debut in Shanghai, China at CGTAsia in April, marking its first entry into the Chinese market. This significant milestone underscores InnoCellular's commitment to expanding its presence in key regions and supporting the growing demand for advanced cell therapy solutions in Asia.

"We are excited to partner with Applitech to offer comprehensive support to the cell therapy community," said Professor LOH Yuin-Han Jonathan, the scientific co-founder of InnoCellular. "Our collaboration combines our strengths in cell culture media with Applitech's expertise in equipment, enabling us to provide integrated solutions that streamline cell therapy manufacturing and accelerate the development of next-generation cell therapies."

"We are delighted to collaborate with InnoCellular in advancing cell therapy technologies to make therapies more comprehensive and affordable," said Mr. XIE Tong CEO of Applitech. "Together, we are well-positioned to meet the evolving needs of researchers and biopharmaceutical companies, empowering them to achieve new heights in cell therapy innovation."

The partnership between InnoCellular and Applitech represents a significant step forward in supporting the advancement of cell and gene therapy technologies, ultimately driving progress towards improved patient care and medical breakthroughs.

For more information about InnoCellular and its initiatives in cell therapy innovation, please visit www.innocellular.com.

For more information about Applitech and its state-of-the-art equipment, please visit <https://en.applitechbio.com/>.

About InnoCellular

At the forefront of advancing therapeutic technologies, InnoCellular Tech Pte Ltd specializes in developing efficient and cost-effective cell culture media for stem cells and specialized cell applications. Renowned for our expertise, we excel in formulating high-performance, consistent, and top-quality biological products essential for pioneering next-generation therapies. Our services encompass a diverse array of options, from ready-to-use or basal formulations, designed for research-only or cGMP purposes, all tailored with unparalleled flexibility to meet your specific experimental or clinical needs.

About Applitech

Applitech Biological Technology Co., Ltd is committed to providing professional biotechnology solutions. Based on the optimization, amplification, and production of biological processes, we insist on improving the product line of the biopharmaceutical field for procedures such as cell culture, process detection, on-line sampling, sample processing.

To meet the needs of the rapid development of the biopharmaceutical industry, Applitech specializes in the development and production of single use Bioreactor, consumables, and other biological process equipment. Applitech has been constantly improving the product line of the biopharmaceutical field to provide users with a full range of professional product solutions. Applitech organizes seminars and training courses every year for industry policy makers and researchers to learn and share technology achievements.

For media queries, please contact:

Tanny KEA

Chief Operating Officer, InnoCellular Tech Pte Ltd

tanny@innocellular.com

SAM Tsz Wing, Sara Ph.D

Manager (Strategic Planning and Communications), InnoCellular Tech Pte Ltd

samtw@innocellular.com

Block 79 Ayer Rajah Crescent, #05-03, Singapore 139955

Genie LUO Ph.D

Director, Cell & Healthcare Department, Applitech Biological Technology Co., Ltd

luojing@applitechpharma.com

No. 483 Xingnan Road, Panyu District, Guangzhou, P.R. China 511442

For general queries, please contact:

(InnoCellular) enquiry@innocellular.com

(Applitech) cell@applitechpharma.com

150 Mount Pleasant Road Singapore 293887

 enquiry@innocellular.com

 www.innocellular.com